CytomX Therapeutics (NASDAQ:CTMX) Trading Down 4.2% on Disappointing Earnings

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down 4.2% during mid-day trading on Tuesday following a dissappointing earnings announcement. The stock traded as low as $6.42 and last traded at $6.4660. 3,381,211 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 5,457,485 shares. The stock had previously closed at $6.75.

The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%.The business had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Strong Phase 1 data — Varsetatug (Varseta‑M) showed confirmed response rates of 32% (10 mg/kg Q3W) and 20% (8.6 mg/kg Q3W) with estimated PFS ~7.1 months at the higher dose; company said FDA interactions are targeted mid‑year to align on a potential registrational trial. This clinical readout is the primary catalyst for the stock rally. GlobeNewswire: Varsetatug data
• Positive Sentiment: Multiple analyst upgrades and price‑target raises — JPMorgan moved CTMX to overweight with a $12 PT, HC Wainwright raised its PT to $17 (buy), and Wedbush lifted its PT to $11 (outperform). These upward revisions amplify investor interest after the clinical update. Benzinga: Analyst price target changes
• Positive Sentiment: Bullish research note — A Seeking Alpha writeup upgraded CTMX to a speculative buy, modeling risk‑adjusted NPV tied to Varseta‑M and estimating a multihandle per‑share valuation based on late‑line mCRC potential. This helps support higher institutional interest. Seeking Alpha: Upgrade/analysis
• Neutral Sentiment: Corporate updates and investor materials — Company released its Q4 results, slide deck and held an earnings call with management commentary and clinical program timelines that investors can review for details. CTMX slide deck / press release
• Negative Sentiment: Planned $250M equity offering — CytomX commenced an underwritten public offering of $250 million in common stock (and pre‑funded warrants for certain investors). While proceeds would fund development, the offering poses dilution risk that can weigh on the share price. GlobeNewswire: Offering announcement
• Negative Sentiment: Q4 earnings and revenue miss — CTMX reported a larger-than-expected loss (EPS -$0.22 vs. est. -$0.08) and revenue of $0.66M versus expectations ~ $7.3M, a near‑term fundamental weakness investors should note. Zacks: Q4 results

Wall Street Analyst Weigh In

CTMX has been the topic of a number of recent research reports. Wedbush raised their target price on CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday. Barclays upped their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Guggenheim reissued a “buy” rating and issued a $10.00 price target on shares of CytomX Therapeutics in a research report on Monday, March 9th. Oppenheimer reaffirmed an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a report on Monday. Finally, Cantor Fitzgerald upped their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC bought a new position in shares of CytomX Therapeutics during the 3rd quarter worth $25,000. Wells Fargo & Company MN raised its stake in CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares during the period. Invesco Ltd. purchased a new stake in CytomX Therapeutics during the second quarter valued at about $32,000. Pursue Wealth Partners LLC bought a new position in CytomX Therapeutics during the second quarter worth about $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in CytomX Therapeutics during the third quarter worth about $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

The stock has a market cap of $1.10 billion, a PE ratio of 16.16 and a beta of 2.44. The firm’s 50 day moving average price is $5.24 and its two-hundred day moving average price is $4.07.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.